ESC Congress 2018 | Day 3 Highlights

Dr. Deepak Bhatt and Prof. Philippe Gabriel Steg discuss ticagrelor and aspirin vs. DAPT followed by aspirin monotherapy (GLOBAL LEADERS); rivaroxaban vs. placebo in HF patients (COMMANDER HF); PAD in critical limb ischemia; tafamidis in transthyretin amyloid cardiomyopathy (ATTR-ACT); percutaneous MV repair in secondary mitral regurgitation and reduced LVEF (MITRA-FR); and a simple risk model to predict CVD or MI in stable CAD (CLARIFY Registry)-American College of Cardiology.
ادامه مطلب »

ESC Congress 2018 | Day 2 Highlights

Dr. Deepak Bhatt and Prof. Philippe Gabriel Steg discuss aspirin for primary CV prevention in diabetics (ASCEND Aspirin); aspirin to reduce risk of initial vascular events (ARRIVE); medically ill patient assessment of rivaroxaban for reducing post-discharge venous thromboembolism (MARINER); omega-3 fatty acids for primary CV prevention in diabetics (ASCEND Omega-3); restrictive vs. liberal red blood cell transfusion in cardiac surgery (TRICS III)-American College of Cardiology
ادامه مطلب »

ESC Congress 2018 | Day 1 Highlights

Dr. Deepak Bhatt and Prof. Philippe Gabriel Steg discuss aspirin for primary CV prevention in diabetics (ASCEND Aspirin); aspirin to reduce risk of initial vascular events (ARRIVE); medically ill patient assessment of rivaroxaban for reducing post-discharge venous thromboembolism (MARINER); omega-3 fatty acids for primary CV prevention in diabetics (ASCEND Omega-3); restrictive vs. liberal red blood cell transfusion in cardiac surgery (TRICS III)
ادامه مطلب »

HEART Pathway implementation associated with decreased hospitalizations

HEART Pathway implementation associated with decreased hospitalizations, increased identification of index visit MIs, and a very low death and MI rate among low-risk patients. These findings support use of the HEART Pathway to identify low-risk patients who can be safely discharged without stress testing or angiography.
ادامه مطلب »

<< صفحه قبلی1 2 3 4 5 6 7 8 9 10 11 صفحه بعدی >>

جستجو

+